Amicus Therapeutics Showcases Innovation at Muscle Society Event
Amicus Therapeutics is set to make a significant impact at the upcoming World Muscle Society Annual Congress, which takes place in Prague, Czechia. The company will present three posters focusing on its innovative development program for Pompe disease, highlighting their continued commitment to advancing treatments for rare diseases. The event will run from October 8 to 12, 2024.
Presentations Highlighting Key Research
One of the most anticipated presentations is titled Cipaglucosidase alfa + miglustat in late-onset Pompe disease: two non-ambulatory patients switching from high-dose, high-frequency alglucosidase alfa, Poster #657P. This study will be presented by Barry J. Byrne, MD, PhD, from the University of Florida. His session is scheduled for Friday, October 11, from 3:45 to 4:45 p.m. CET.
Details on the Poster Session
During this poster session, attendees will have the opportunity to delve into cutting-edge research focused on the efficacy of combinations of therapies for patients with Pompe disease. The location for this session is Forum Hall at The Prague Congress Centre.
Further Research Outcomes Shared
Another notable abstract being presented is titled Post-baseline outcomes of the UK Early Access to Medicines Scheme registry for cipaglucosidase alfa plus miglustat in late-onset Pompe disease, Poster #670P. Mark Roberts, MD, from the Salford Royal NHS Foundation Trust in the UK, will discuss the findings during his session at the same time, providing insights into the real-world applications of these treatments.
Innovative Enzyme Stabilizers Uncovered
Additionally, Tahseen Mozaffar, MD, from the University of California, Irvine, will present another compelling study, Miglustat: a first-in-class enzyme stabilizer for late-onset Pompe disease, Poster #671P. This presentation will also be part of the session on October 11, aiming to explore the potential of new therapeutic options.
About Amicus Therapeutics
Amicus Therapeutics is a biotechnology company that is dedicated to discovering and delivering innovative medicines that cater to the needs of patients living with rare diseases. With a strong emphasis on patient care and a pipeline filled with potential first- or best-in-class therapies, Amicus Therapeutics continues to make strides in the biopharmaceutical landscape. The company’s commitment to advancing treatments like those for Pompe disease highlights their overall mission to improve patient outcomes and quality of life.
Company Growth and Advancements
The development and research efforts of Amicus Therapeutics reinforce their leadership position in the biotechnology sector. By participating in key conferences like the World Muscle Society Congress, they not only share their findings but also gain valuable insights from peers, further enriching their research and development initiatives.
Stay Informed on Amicus Therapeutics
For those interested in learning more about the company’s innovations and research initiatives, checking their website will provide the most up-to-date information. Amicus Therapeutics maintains a strong online presence where stakeholders can follow their progress and contributions to the biopharmaceutical field.
Contact Information
For inquiries, stakeholders can reach out directly to Andrew Faughnan, Vice President of Investor Relations, at (609) 662-3809. Any media inquiries can be directed to Diana Moore, Head of Global Corporate Communications, at the same phone line. They are both committed to facilitating communication between the company and interested parties.
Frequently Asked Questions
What is the focus of the Amicus Therapeutics presentations at the Congress?
The focus is on the development program for Pompe disease, featuring innovative research and treatment combinations.
When will the poster sessions occur?
The poster sessions are scheduled for Friday, October 11, from 3:45 to 4:45 p.m. CET.
Where is the Congress taking place?
The World Muscle Society Annual Congress will be held at The Prague Congress Centre in Prague, Czechia.
Who are the presenters of the posters?
The presenters include Barry J. Byrne, Mark Roberts, and Tahseen Mozaffar, all well-respected professionals in their respective fields.
How can I find out more about Amicus Therapeutics?
More information can be obtained from their official website, where they share updates on their research and initiatives.
